PFE Stock Analysis — Pfizer Inc.
Sector: Healthcare
AI Verdict
Pfizer trades at a steep discount to the sector on next year's earnings, but the market is betting on a massive profit rebound—if that doesn't materialize, the current optimism could unwind fast.
Competitive Moat
Pfizer's moat comes from its deep patent portfolio and global scale in drug development, manufacturing, and distribution. Its established regulatory relationships and ability to commercialize blockbuster drugs give it a durable edge in a highly regulated industry.
Summary
Pfizer is on watch as analysts expect a massive 341.4% jump in earnings over the next year.
Where It Stands
Pfizer is up 16.22% over the past year, trades at 8.6x next year's earnings (well below the healthcare median of 22x), and its RSI of 71.2 signals overbought territory.
Key Metrics
- RSI: 71.2 — Overbought
- Trailing P/E: 38.1x
- Forward P/E: 8.6x
- PEG Ratio: 0.11
- Earnings Growth: +3.4%
- Revenue Growth: -0.0%
- Market Cap: $164.2B
- Dividend Yield: 0.05%
- 1-Year Return: 16.22%
- 52-Week High: $29.09
- 52-Week Low: $23.58
Analyst Consensus
14 Buy · 20 Hold · 2 Sell (36 analysts) · Target $31.00
Bull Case
With forward EPS growth forecast at 341.4% and a forward P/E of just 8.6x, you're paying a low price for a huge earnings rebound if consensus holds.
Bear Case
If the forward P/E reverts even halfway to the sector median (from 8.6x to 15x), the stock could see a sharp pullback, especially with an RSI of 71.2 flagging elevated risk.
Catalyst to Watch
Watch for upcoming drug approvals or earnings reports that confirm or challenge the 341.4% EPS growth expectation.